Starting Azilect early delays progression of Parkinson's
This article was originally published in Scrip
Early treatment with Tevaand Lundbeck's Azilect (rasagiline) delays the progression of Parkinson's disease, new data suggest.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.